	Application No.	ion No. Applicant(s)	
Notice of Allowability	09/913,516	IGA ET AL.	
	Examiner	Art Unit	
	Konata M. George	1616	
The MAILING DATE of this communication apperature All claims being allowable, PROSECUTION ON THE MERITS IS herewith (or previously mailed), a Notice of Allowance (PTOL-85) NOTICE OF ALLOWABILITY IS NOT A GRANT OF PATENT RIOF of the Office or upon petition by the applicant. See 37 CFR 1.313	(OR REMAINS) CLOSED in to or other appropriate communication. This application is sul	his application. If not includication will be mailed in due	ded e course. THIS
1. X This communication is responsive to <u>applicants response filed May 29, 2007</u> .			
2. X The allowed claim(s) is/are 8, 11-13, 15, 16, 18-34, 38 and	<u>139</u> .		
 3. Acknowledgment is made of a claim for foreign priority ur a) All b) Some* c) None of the: 1. Certified copies of the priority documents have 2. Certified copies of the priority documents have 3. Copies of the certified copies of the priority documents 	e been received. e been received in Application	No	eation from the
International Bureau (PCT Rule 17.2(a)).			
* Certified copies not received:			
Applicant has THREE MONTHS FROM THE "MAILING DATE" of this communication to file a reply complying with the requirements noted below. Failure to timely comply will result in ABANDONMENT of this application. THIS THREE-MONTH PERIOD IS NOT EXTENDABLE.			
4. A SUBSTITUTE OATH OR DECLARATION must be submitted. Note the attached EXAMINER'S AMENDMENT or NOTICE OF INFORMAL PATENT APPLICATION (PTO-152) which gives reason(s) why the oath or declaration is deficient.			
5. CORRECTED DRAWINGS (as "replacement sheets") must be submitted.			
(a) ☐ including changes required by the Notice of Draftsperson's Patent Drawing Review (PTO-948) attached			
1) hereto or 2) to Paper No./Mail Date			
(b) ☐ including changes required by the attached Examiner's Paper No./Mail Date			
Identifying indicia such as the application number (see 37 CFR 1.84(c)) should be written on the drawings in the front (not the back) of each sheet. Replacement sheet(s) should be labeled as such in the header according to 37 CFR 1.121(d).			
6. DEPOSIT OF and/or INFORMATION about the deposit of BIOLOGICAL MATERIAL must be submitted. Note the attached Examiner's comment regarding REQUIREMENT FOR THE DEPOSIT OF BIOLOGICAL MATERIAL.			
		·	
	•		
Attachment(s) 1. Notice of References Cited (PTO-892)	5. Notice of Info	rmal Patent Application	·
2. ☐ Notice of Draftperson's Patent Drawing Review (PTO-948)	6. 🔲 Interview Sun	nmary (PTO-413),	
3. Information Disclosure Statements (PTO/SB/08),	Paper No./M 7. ⊠ Examiner's A	ail Date mendment/Comment	
Paper No./Mail Date		tatement of Reasons for Al	llowance
Sel telebrite sugares			

DETAILED ACTION

Claims 8, 11-13, 15, 16, 18-34, 38 and 39 are pending in this application.

Action Summary

1. The rejection of claims 8, 11-13, 15, 16, 18-34, 38 and 39 under 35 U.S.C. 103(a) as being unpatentable over SmithKline Beecham Co. (WO 95/06410) in view of Sekine et al. (WO 97/28794 as translated by US 6,054,484) and RxList Monographs is hereby withdrawn in view of applicants arguments.

Examiner's Amendment

2. An examiner's amendment to the record appears below. Should that changes and/or additions be unacceptable to applicant, an amendment may be filed as provided by 37 CFR 1.312. To ensure consideration of such an amendment, it MUST be submitted no later than the payment of the issue fee.

Authorization for this examiner's amendment was given in a telephone interview with Alexey Sapriginon September 28, 2007.

Amend the claims as follows:

IN THE CLAIMS:

In claim 29, line 1, delete "A" and insert "The"

Application/Control Number: 09/913,516

Art Unit: 1616

Statement of Reasons for Allowance

3. The following is an examiner's statement of reasons for allowance:

The claims are allowable over the cited prior art because the prior art does not teach, disclose nor make obvious a percutaneous absorption preparation comprising a compound having angiotension II antagonistic activity and a skin permeability regular and support, wherein the skin permeability regular comprises a fatty acid ester, a polyol and a nonionic surfactant and wherein the compound having angiotension II antagonistic activity is 1-(cyclohexyloxycarbonyloxy)ethyl 2-ethoxy-1-[[2'-(1H-tetrazol-5-yl)biphenyl-4-yl]methyl]benzimidazole-7-carboxylate. The closest prior art reference of SmithKline Beecham Co. does not teach the carboxylate together with the skin permeability regular as claimed.

Any comments considered necessary by applicant must be submitted no later than the payment of the issue fee and, to avoid processing delays, should preferably accompany the issue fee. Such submissions should be clearly labeled "Comments on Statement of Reasons for Allowance."

Conclusion

4. Claims 8, 11-13, 15, 16, 18-34, 38 and 39 are allowed.

Telephone Inquiries

Any inquiry concerning this communication or earlier communications from the examiner should be directed to Konata M. George, whose telephone number is 571-

Application/Control Number: 09/913,516

Art Unit: 1616

272-0613. The examiner can normally be reached from 8:00AM to 6:30PM Monday to

Thursday.

If attempts to reach the examiner by telephone are unsuccessful, the examiner's

Page 4

supervisor, Johann R. Richter, can be reached at 571-272-0646. The fax phone

numbers for the organization where this application or proceeding is assigned is 571-

273-8300.

Information regarding the status of an application may be obtained from the

Patent Application Information Retrieval (PAIR) system. Status information for

published applications may be obtained from either Private PAIR or Public PAIR.

Status information for unpublished applications is available through Private PAIR

For more information about the PAIR system, see http://pair-direct.uspto.gov.

Should you have question on access to the Private Pair system, contact the Electronic

Business Center (EBC) at 866-217-9197 (toll-free).

Konata M. George Patent Examiner Art Unit 1616

Johann R. Richter

Supervisory Patent Examiner

Art Unit 1616